Invention Grant
US09073939B2 Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
有权
吲唑基取代的二氢异恶唑并吡咯嗪及其使用方法
- Patent Title: Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
- Patent Title (中): 吲唑基取代的二氢异恶唑并吡咯嗪及其使用方法
-
Application No.: US13383223Application Date: 2010-07-07
-
Publication No.: US09073939B2Publication Date: 2015-07-07
- Inventor: Martin Michels , Markus Follmann , Alexandros Vakalopoulos , Katja Zimmermann , Nicole Teusch , Mario Lobell
- Applicant: Martin Michels , Markus Follmann , Alexandros Vakalopoulos , Katja Zimmermann , Nicole Teusch , Mario Lobell
- Applicant Address: DE Monheim
- Assignee: Bayer Intellectual Property GmbH
- Current Assignee: Bayer Intellectual Property GmbH
- Current Assignee Address: DE Monheim
- Priority: EP09008996 20090710
- International Application: PCT/EP2010/004147 WO 20100707
- International Announcement: WO2011/003604 WO 20110113
- Main IPC: C07D498/04
- IPC: C07D498/04 ; A61K31/437
Abstract:
This invention relates to novel 4-(indazol-5-yl)-4,7-dihydroisoxazolo[5,4-b]pyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
Public/Granted literature
- US20120190709A1 Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof Public/Granted day:2012-07-26
Information query
